Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Fase 3 forlængelsesundersøgelse til evaluering af langsigtet sikkerhed af Ianalumab hos deltagere med systemisk lupus erythematosus (SIRIUS-SLE forlængelse). (SIRIUS-SLE LTE)

6. november 2026 opdateret af: Novartis Pharmaceuticals

A Randomized, Double-blind, Placebo-controlled Extension Study, Followed by a Study Treatment Withdrawal or Open-label Period, to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).

Studieoversigt

Status

Rekruttering

Detaljeret beskrivelse

The purpose of this extension study is to evaluate long-term safety and tolerability of ianalumab administered s.c. monthly or quarterly, compared to monthly placebo, in adolescent and adult participants with anti-nuclear antibody (ANA)-positive systemic lupus erythematosus of moderate-to-severe disease activity, who have completed either CVAY736F12301 (SIRIUS-SLE 1) or CVAY736F12302 (SIRIUS-SLE 2) core studies.

This extension study will last up to 7 years and includes the following three treatment periods:

  • a 3-year double-blind, randomized, placebo-controlled treatment period, evaluating the safety and efficacy of ianalumab or placebo (Period 1);
  • followed by a 2-year treatment period evaluating safety and efficacy of treatment withdrawal and open-label ianalumab administered s.c. monthly.
  • and an up to 2-year open-label, safety monitoring period (Period 3).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

550

Fase

  • Fase 3

Udvidet adgang

Ledig uden for det kliniske forsøg. Se udvidet adgangsregistrering.

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

      • Caba, Argentina, C1015ABO
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Caba, Argentina, C1427CCL
        • Rekruttering
        • Novartis Investigative Site
      • San Miguel de Tucumán, Argentina, T4000AXL
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Buenos Aires
      • La Plata, Buenos Aires, Argentina, B1900AWT
        • Rekruttering
        • Novartis Investigative Site
      • Quilmes, Buenos Aires, Argentina, 1878
        • Rekruttering
        • Novartis Investigative Site
      • San Miguel, Buenos Aires, Argentina, B1663GKT
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Tucumán Province
      • San Miguel, Tucumán Province, Argentina, T4000CBC
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Queensland
      • Maroochydore, Queensland, Australien, 4558
        • Rekruttering
        • Novartis Investigative Site
      • Salvador, Brasilien, 40323-010
        • Rekruttering
        • Novartis Investigative Site
    • Espírito Santo
      • Vitória, Espírito Santo, Brasilien, 29055-450
        • Rekruttering
        • Novartis Investigative Site
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasilien, 40150-150
        • Rekruttering
        • Novartis Investigative Site
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasilien, 30150-221
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, Brasilien, 80030-110
        • Rekruttering
        • Novartis Investigative Site
    • Rio de Janeiro
      • Niterói, Rio de Janeiro, Brasilien, 24020-096
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Rio de Janeiro, Rio de Janeiro, Brasilien, 22211-230
        • Rekruttering
        • Novartis Investigative Site
    • São Paulo
      • Barretos, São Paulo, Brasilien, 14784-400
        • Rekruttering
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasilien, 04038-002
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasilien, 01244-030
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Sofia, Bulgarien, 1431
        • Rekruttering
        • Novartis Investigative Site
    • Bulgaria
      • Plovdiv, Bulgaria, Bulgarien, 4002
        • Rekruttering
        • Novartis Investigative Site
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1L7
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Ontario
      • Toronto, Ontario, Canada, M5T 2S8
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Quebec
      • Rimouski, Quebec, Canada, G5L 5T1
        • Rekruttering
        • Novartis Investigative Site
    • Los Ríos Region
      • Valdivia, Los Ríos Region, Chile, 5110683
        • Rekruttering
        • Novartis Investigative Site
    • RM
      • Santiago, RM, Chile, 7500588
        • Rekruttering
        • Novartis Investigative Site
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile, 7500710
        • Rekruttering
        • Novartis Investigative Site
      • Bogotá, Colombia, 111211
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Antioquia
      • Medellín, Antioquia, Colombia, 050001
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Atlántico
      • Barranquilla, Atlántico, Colombia, 080020
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Cundinamarca
      • Chía, Cundinamarca, Colombia, 250001
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Santander Department
      • Bucaramanga, Santander Department, Colombia, 680003
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colombia, 760046
        • Rekruttering
        • Novartis Investigative Site
    • Alabama
      • Anniston, Alabama, Forenede Stater, 36207
        • Rekruttering
        • Pinnacle Research Group Llc
        • Ledende efterforsker:
          • Vishala L Chindalore
        • Kontakt:
    • California
      • Burbank, California, Forenede Stater, 91505
        • Rekruttering
        • Providence Medical Center
        • Ledende efterforsker:
          • Sue Chung
        • Kontakt:
      • La Palma, California, Forenede Stater, 90623
        • Rekruttering
        • Advanced Medical Research
        • Ledende efterforsker:
          • Gerald Ho
        • Kontakt:
      • Westlake Village, California, Forenede Stater, 91361
        • Aktiv, ikke rekrutterende
        • Millennium Clinical Trials
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • University of Colorado Denver
        • Ledende efterforsker:
          • Christopher Striebich
        • Kontakt:
    • Florida
      • Clearwater, Florida, Forenede Stater, 33765
        • Rekruttering
        • Clinical Res Of W Florida
        • Ledende efterforsker:
          • Robert Levin
        • Kontakt:
      • Cooper City, Florida, Forenede Stater, 33024
        • Rekruttering
        • GNP Research
        • Ledende efterforsker:
          • Mark Jaffe
        • Kontakt:
      • Homestead, Florida, Forenede Stater, 33033
        • Rekruttering
        • Homestead Assoc In Research Inc
        • Ledende efterforsker:
          • Gilberto Seco
        • Kontakt:
      • Plantation, Florida, Forenede Stater, 33324
        • Rekruttering
        • IRIS Research and Development
        • Ledende efterforsker:
          • Guillermo Valenzuela
        • Kontakt:
      • Tampa, Florida, Forenede Stater, 33603
        • Rekruttering
        • Clinical Research of West Florida Inc
        • Ledende efterforsker:
          • John Carter
        • Kontakt:
    • Georgia
      • Lawrenceville, Georgia, Forenede Stater, 30044
        • Rekruttering
        • Parris and Associates Rheumatology
        • Ledende efterforsker:
          • Glenn Parris
        • Kontakt:
    • Illinois
      • Skokie, Illinois, Forenede Stater, 60076
        • Afsluttet
        • Robert A Hozman MD SC
      • Willowbrook, Illinois, Forenede Stater, 60527
        • Rekruttering
        • Willow Rheumatology Wellness
        • Ledende efterforsker:
          • Angela R Crowley
        • Kontakt:
    • Louisiana
      • Lake Charles, Louisiana, Forenede Stater, 70601
      • New Orleans, Louisiana, Forenede Stater, 70112
        • Aktiv, ikke rekrutterende
        • UMC New Orleans
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
        • Aktiv, ikke rekrutterende
        • University Of Maryland
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48202
        • Rekruttering
        • Henry Ford Health
        • Ledende efterforsker:
          • Alireza Meysami
        • Kontakt:
      • Grand Blanc, Michigan, Forenede Stater, 48439
        • Rekruttering
        • Ahmed Arif Medical Research Center
        • Ledende efterforsker:
          • Ali Karrar
        • Kontakt:
          • Iman Abdelrahman
          • Telefonnummer: +1 810 953 8700
          • E-mail: iman@aamrc.net
    • Ohio
      • Middleburg Heights, Ohio, Forenede Stater, 44130
        • Rekruttering
        • Paramount Med Rsrch and Consult LLC
        • Ledende efterforsker:
          • Isam Diab
        • Kontakt:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • Rekruttering
        • University Of Pittsburgh
        • Ledende efterforsker:
          • Andreea Coca
        • Kontakt:
    • Tennessee
      • Jackson, Tennessee, Forenede Stater, 38305
        • Rekruttering
        • West Tennessee Research Institute
        • Ledende efterforsker:
          • Jacob A Aelion
        • Kontakt:
      • Memphis, Tennessee, Forenede Stater, 38119
        • Rekruttering
        • Shelby Research LLC
        • Ledende efterforsker:
          • Ramesh C Gupta
        • Kontakt:
    • Texas
      • Bellaire, Texas, Forenede Stater, 77401
        • Rekruttering
        • Novel Research LLC
        • Ledende efterforsker:
          • Wajeeha Yousaf
        • Kontakt:
      • League City, Texas, Forenede Stater, 77573
      • Red Oak, Texas, Forenede Stater, 75154
        • Rekruttering
        • Epic Medical Research
        • Ledende efterforsker:
          • Sunny Patel
        • Kontakt:
      • Montpellier, Frankrig, 34295
        • Rekruttering
        • Novartis Investigative Site
      • Paris, Frankrig, 75014
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Paris, Frankrig, 75013
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Toulouse, Frankrig, 31059
        • Rekruttering
        • Novartis Investigative Site
      • Toulouse, Frankrig, 31054
        • Rekruttering
        • Novartis Investigative Site
      • Guatemala City, Guatemala, 01010
        • Rekruttering
        • Novartis Investigative Site
    • Departamento de Guatemala
      • Guatemala City, Departamento de Guatemala, Guatemala, 01010
        • Rekruttering
        • Novartis Investigative Site
      • New Delhi, Indien, 110075
        • Rekruttering
        • Novartis Investigative Site
    • Gujarat
      • Ahmedabad, Gujarat, Indien, 380015
        • Rekruttering
        • Novartis Investigative Site
      • Ahmedabad, Gujarat, Indien, 380006
        • Rekruttering
        • Novartis Investigative Site
    • Kerala
      • Kozhikode, Kerala, Indien, 673008
        • Rekruttering
        • Novartis Investigative Site
    • Maharashtra
      • Kolhāpur, Maharashtra, Indien, 416001
        • Rekruttering
        • Novartis Investigative Site
      • Nagpur, Maharashtra, Indien, 441108
        • Rekruttering
        • Novartis Investigative Site
      • Nashik, Maharashtra, Indien, 422101
        • Rekruttering
        • Novartis Investigative Site
      • Pune, Maharashtra, Indien, 411001
        • Rekruttering
        • Novartis Investigative Site
      • Pune, Maharashtra, Indien, 411007
        • Rekruttering
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Indien, 110060
        • Rekruttering
        • Novartis Investigative Site
    • New Delhi
      • New Delhi, New Delhi, Indien, 110029
        • Rekruttering
        • Novartis Investigative Site
    • Uttarakhand
      • Dehradun, Uttarakhand, Indien, 248001
        • Rekruttering
        • Novartis Investigative Site
      • Haifa, Israel, 3109601
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Ramat Gan, Israel, 5265601
        • Rekruttering
        • Novartis Investigative Site
    • FE
      • Cona, FE, Italien, 44124
        • Rekruttering
        • Novartis Investigative Site
    • PD
      • Padova, PD, Italien, 35128
        • Rekruttering
        • Novartis Investigative Site
    • PI
      • Pisa, PI, Italien, 56126
        • Rekruttering
        • Novartis Investigative Site
    • RM
      • Roma, RM, Italien, 00152
        • Rekruttering
        • Novartis Investigative Site
    • TO
      • Torino, TO, Italien, 10128
        • Rekruttering
        • Novartis Investigative Site
      • Miyazaki, Japan, 8891692
        • Rekruttering
        • Novartis Investigative Site
      • Osaka, Japan, 5458586
        • Rekruttering
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 4578510
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Nagoya, Aichi-ken, Japan, 4578511
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 0608648
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 2360004
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Miyagi
      • Sendai, Miyagi, Japan, 9838512
        • Rekruttering
        • Novartis Investigative Site
    • Tokyo
      • Bunkyo-ku, Tokyo, Japan, 1138519
        • Rekruttering
        • Novartis Investigative Site
      • Chuo Ku, Tokyo, Japan, 1048560
        • Rekruttering
        • Novartis Investigative Site
      • Fuchū, Tokyo, Japan, 1838524
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Shinjuku-ku, Tokyo, Japan, 1608582
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • tabashi City, Tokyo, Japan, 1738610
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Beijing, Kina, 100730
        • Rekruttering
        • Novartis Investigative Site
      • Beijing, Kina, 100069
        • Rekruttering
        • Novartis Investigative Site
      • Shanghai, Kina, 200001
        • Rekruttering
        • Novartis Investigative Site
      • Xinxiang, Kina, 453099
        • Rekruttering
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510080
        • Rekruttering
        • Novartis Investigative Site
      • Guangzhou, Guangdong, Kina, 510000
        • Rekruttering
        • Novartis Investigative Site
      • Shantou, Guangdong, Kina, 515000
        • Rekruttering
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210008
        • Rekruttering
        • Novartis Investigative Site
      • Suzhou, Jiangsu, Kina, 215004
        • Rekruttering
        • Novartis Investigative Site
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330006
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Pingxiang, Jiangxi, Kina, 337000
        • Rekruttering
        • Novartis Investigative Site
    • Jilin
      • Changchun, Jilin, Kina, 130021
        • Rekruttering
        • Novartis Investigative Site
    • Shandong
      • Linyi, Shandong, Kina, 276100
        • Rekruttering
        • Novartis Investigative Site
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Rekruttering
        • Novartis Investigative Site
    • Xinjiang
      • Ürümqi, Xinjiang, Kina, 830001
        • Rekruttering
        • Novartis Investigative Site
    • Zhejiang
      • Ningbo, Zhejiang, Kina, 315016
        • Rekruttering
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, Kina, 325000
        • Rekruttering
        • Novartis Investigative Site
    • Perak
      • Ipoh, Perak, Malaysia, 30450
        • Rekruttering
        • Novartis Investigative Site
      • México, Mexico, 07760
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Guanajuato
      • León, Guanajuato, Mexico, 37160
        • Rekruttering
        • Novartis Investigative Site
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44160
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Mexico City
      • Mexico City, Mexico City, Mexico, 06700
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Michoacán
      • Morelia, Michoacán, Mexico, 58000
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
    • Yucatán
      • Mérida, Yucatán, Mexico, 97070
        • Rekruttering
        • Novartis Investigative Site
      • Bydgoszcz, Polen, 85-065
        • Rekruttering
        • Novartis Investigative Site
      • Bydgoszcz, Polen, 85-168
        • Rekruttering
        • Novartis Investigative Site
      • Bytom, Polen, 41 902
        • Rekruttering
        • Novartis Investigative Site
      • Warsaw, Polen, 00-874
        • Rekruttering
        • Novartis Investigative Site
      • Warsaw, Polen, 04-141
        • Rekruttering
        • Novartis Investigative Site
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Polen, 52-210
        • Rekruttering
        • Novartis Investigative Site
      • Braga, Portugal, 4710-243
        • Rekruttering
        • Novartis Investigative Site
      • Lisbon, Portugal, 1050-034
        • Rekruttering
        • Novartis Investigative Site
      • Brasov, Rumænien, 500283
        • Rekruttering
        • Novartis Investigative Site
      • Bucharest, Rumænien, 011172
        • Rekruttering
        • Novartis Investigative Site
    • Cluj
      • Cluj-Napoca, Cluj, Rumænien, 400006
        • Rekruttering
        • Novartis Investigative Site
      • Bratislava, Slovakiet, 811 08
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Košice, Slovakiet, 040 01
        • Aktiv, ikke rekrutterende
        • Novartis Investigative Site
      • Barcelona, Spanien, 08035
        • Rekruttering
        • Novartis Investigative Site
      • Madrid, Spanien, 28034
        • Rekruttering
        • Novartis Investigative Site
      • Valencia, Spanien, 46014
        • Rekruttering
        • Novartis Investigative Site
    • A Coruna
      • Santiago Compostela, A Coruna, Spanien, 15706
        • Rekruttering
        • Novartis Investigative Site
    • Barcelona
      • Badalona, Barcelona, Spanien, 08916
        • Rekruttering
        • Novartis Investigative Site
    • Cantabria
      • Santander, Cantabria, Spanien, 39008
        • Rekruttering
        • Novartis Investigative Site
    • Catalonia
      • Barcelona, Catalonia, Spanien, 08003
        • Rekruttering
        • Novartis Investigative Site
    • Madrid
      • San Sebastian Reyes, Madrid, Spanien, 28702
        • Rekruttering
        • Novartis Investigative Site
      • Umhlanga, Sydafrika, 4320
        • Rekruttering
        • Novartis Investigative Site
    • Gauteng
      • Pretoria, Gauteng, Sydafrika, 0002
        • Rekruttering
        • Novartis Investigative Site
    • Western Cape
      • Cape Town, Western Cape, Sydafrika, 7500
        • Rekruttering
        • Novartis Investigative Site
      • Cape Town, Western Cape, Sydafrika, 7405
        • Rekruttering
        • Novartis Investigative Site
      • Somerset West, Western Cape, Sydafrika, 7130
        • Rekruttering
        • Novartis Investigative Site
      • Gwangju, Sydkorea, 61469
        • Afsluttet
        • Novartis Investigative Site
      • Seoul, Sydkorea, 06591
        • Rekruttering
        • Novartis Investigative Site
      • Seoul, Sydkorea, 04763
        • Rekruttering
        • Novartis Investigative Site
      • Kaohsiung City, Taiwan, 833
        • Rekruttering
        • Novartis Investigative Site
      • Taichung, Taiwan, 40447
        • Rekruttering
        • Novartis Investigative Site
      • Taichung, Taiwan, 407219
        • Rekruttering
        • Novartis Investigative Site
      • Taipei, Taiwan, 10002
        • Rekruttering
        • Novartis Investigative Site
      • Taipei, Taiwan, 11217
        • Rekruttering
        • Novartis Investigative Site
      • Taoyuan, Taiwan, 33305
        • Rekruttering
        • Novartis Investigative Site
      • Bangkok, Thailand, 10400
        • Rekruttering
        • Novartis Investigative Site
      • Bangkok, Thailand, 10700
        • Rekruttering
        • Novartis Investigative Site
    • Hat Yai
      • Songkhla, Hat Yai, Thailand, 90110
        • Rekruttering
        • Novartis Investigative Site
    • Thailand
      • Muang, Thailand, Thailand, 12120
        • Rekruttering
        • Novartis Investigative Site
      • Brno, Tjekkiet, 638 00
        • Rekruttering
        • Novartis Investigative Site
      • Prague, Tjekkiet, 128 00
        • Rekruttering
        • Novartis Investigative Site
      • Uherské Hradiště, Tjekkiet, 686 01
        • Rekruttering
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Tyskland, 50937
        • Trukket tilbage
        • Novartis Investigative Site
    • Saxony
      • Leipzig, Saxony, Tyskland, 04103
        • Rekruttering
        • Novartis Investigative Site
      • Budapest, Ungarn, 1134
        • Rekruttering
        • Novartis Investigative Site
      • Gyula, Ungarn, 5700
        • Rekruttering
        • Novartis Investigative Site
      • Zalaegerszeg, Ungarn, 8900
        • Rekruttering
        • Novartis Investigative Site
    • Fejér
      • Székesfehérvár, Fejér, Ungarn, 8000
        • Rekruttering
        • Novartis Investigative Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år til 100 år (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants <18 years of age. Of note, if the participant reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
  • Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation.
  • In the judgement of the investigator, participants must be expected to clinically benefit from continued study treatment.

Key Exclusion Criteria:

  • Use of prohibited therapies.
  • Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.
  • Plans for administration of live vaccines during the study period.
  • Pregnant or nursing (lactating) women.

Other protocol-defined inclusion/exclusion criteria may apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Ianalumab monthly

Ianalumab s.c. monthly

Ianalumab s.c. monthly Ianalumab s.c. quarterly

Andre navne:
  • VAY736
Eksperimentel: Ianalumab quarterly

Ianalumab s.c. quarterly

Ianalumab s.c. monthly Ianalumab s.c. quarterly

Andre navne:
  • VAY736
Placebo komparator: Placebo monthly

Placebo s.c. monthly

Placebo s.c. monthly

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of treatment-emergent Adverse events/Serious Adverse events
Tidsramme: through study completion, up to approximately 324 weeks

Assessment of long-term safety and tolerability of ianalumab

through study completion, up to approximately 324 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of participants who achieved Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response
Tidsramme: up to Week 324

SRI-4 response is defined as:

  • Systemic Lupus Erythematosus Disease Activity Index - 2000 (SLEDAI-2K) reduction from baseline of ≥ 4 points
  • No British Isles Lupus Assessment Group-2004 (BILAG-2004) worsening, defined as ≥ 1 new A or ≥ 2 new B items compared to baseline
  • No worsening in Physician Global Assessment of Disease Activity (PhGA), defined as an increase of ≥ 0.3 from baseline on a 0 to 3 visual analog scale
up to Week 324
Proportion of participants who achieved Definition of Remission in SLE (DORIS) response
Tidsramme: up to Week 324

DORIS is defined as:

  • Clinical SLEDAI (cSLEDAI) = 0 (excluding serological items, anti-dsDNA and complement)
  • Physician global assessment (PhGA, scale 0-3) < 0.5
  • Current CS (predniso(lo)ne or equivalent) dose ≤ 5 mg/day
  • Patient may be on antimalarials, low dose glucocorticoids and/or stable immune-suppressive treatment including biologics.
up to Week 324
Change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index
Tidsramme: up to Week 324

SLICC/ACR Damage Index is a measure of cumulative damage due to SLE

up to Week 324
Average daily dose of corticosteroids administered
Tidsramme: up to Week 324

Evaluating the effect of ianalumab on corticosteroids intake

up to Week 324
Annualized BILAG moderate or severe flare rate
Tidsramme: up to Week 324

Annualized BILAG moderate or severe flare rate where moderate BILAG flare is defined as 2 or more new BILAG-2004 B items, and severe BILAG flare is defined as 1 or more new BILAG-2004 A items, compared to the previous visit

up to Week 324
Ianalumab serum concentrations during treatment and follow-up after last dose
Tidsramme: up to Week 324

To characterize the Pharmacokinetics (PK) of ianalumab

up to Week 324
Incidence and titer of anti-ianalumab antibodies in serum (ADA assay) over time.
Tidsramme: up to Week 324

To characterize the immunogenicity of ianalumab

up to Week 324

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. maj 2024

Primær færdiggørelse (Anslået)

3. april 2034

Studieafslutning (Anslået)

2. oktober 2034

Datoer for studieregistrering

Først indsendt

2. oktober 2023

Først indsendt, der opfyldte QC-kriterier

15. november 2023

Først opslået (Faktiske)

18. november 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CVAY736F12301E1
  • 2023-505929-14-00 (Registry Identifier: EU CT NUMBER)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner